Akiko Honobe‐Tabuchi
A5090552001- Cancer Immunotherapy and Biomarkers
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- RNA Interference and Gene Delivery
- Immune cells in cancer
- Cytomegalovirus and herpesvirus research
- Inflammatory Biomarkers in Disease Prognosis
- Single-cell and spatial transcriptomics
- Hepatitis B Virus Studies
- Cancer Genomics and Diagnostics
- Monoclonal and Polyclonal Antibodies Research
- Autoimmune Bullous Skin Diseases
- Ocular Diseases and Behçet’s Syndrome
- Allergic Rhinitis and Sensitization
- Dermatology and Skin Diseases
- Food Allergy and Anaphylaxis Research
- Mast cells and histamine
- Pharmacogenetics and Drug Metabolism
- T-cell and B-cell Immunology
- Otitis Media and Relapsing Polychondritis
- Infectious Diseases and Tuberculosis
- Nanoplatforms for cancer theranostics
- Cancer Treatment and Pharmacology
- Urticaria and Related Conditions
University of Yamanashi
2021-2025
University of Yamanashi Hospital
2023
ABSTRACT Regulatory T (T reg ) cells have an immunosuppressive function, and programmed death‐1 (PD‐1)‐expressing reportedly induce resistance to PD‐1 blockade therapies through their reactivation. However, the effects of antigenicity on expression in therapy remain unclear. Here, we show that gain high antigen with antigenicity. Additionally, tumors for were resistant vivo due + ‐cell infiltration. Because such cytotoxic lymphocyte (CTLA)‐4 expression, could be overcome by combination...
Some patients experience mixed response to immunotherapy, whose biological mechanisms and clinical impact have been obscure. We obtained two tumor samples from lymph node (LN) metastatic lesions in a same patient. Whole exome sequencing for the both tumors single-cell tumor-infiltrating lymphocytes (TIL) demonstrated significant difference clonality TILs' characteristics, especially exhausted T-cell clonotypes, although close relationship between cell clones were observed as of an overlapped...
T-cell exhaustion is a major contributor to immunosuppression in the tumor microenvironment (TME). Blockade of key regulators exhaustion, such as programmed death 1, can reinvigorate tumor-specific T cells and activate antitumor immunity various types cancer. In this study, we identified that CD106 was specifically expressed exhausted CD8+ TME using single-cell RNA sequencing. High expression clinical samples corresponded improved response cancer immunotherapy. suppressed both vitro vivo,...
<div>Abstract<p>T-cell exhaustion is a major contributor to immunosuppression in the tumor microenvironment (TME). Blockade of key regulators T-cell exhaustion, such as programmed death 1, can reinvigorate tumor-specific T cells and activate antitumor immunity various types cancer. In this study, we identified that CD106 was specifically expressed exhausted CD8<sup>+</sup> TME using single-cell RNA sequencing. High expression clinical samples corresponded improved...
<div>Abstract<p>T-cell exhaustion is a major contributor to immunosuppression in the tumor microenvironment (TME). Blockade of key regulators T-cell exhaustion, such as programmed death 1, can reinvigorate tumor-specific T cells and activate antitumor immunity various types cancer. In this study, we identified that CD106 was specifically expressed exhausted CD8<sup>+</sup> TME using single-cell RNA sequencing. High expression clinical samples corresponded improved...
<p>Additional scRNA-seq data</p>
<p>Additional scRNA-seq data</p>
<p>LAG3, HAVCR2, TIGIT, TNFRSF9, ENTPD1, and ITGAE expression using our scRNA-seq data volcano plots (exhausted CD8+ T-cell vs. the others) publicly available datasets</p>
<p>Multiplexed fluorescent immunohistochemistry</p>
<p>Influence of CD106 on various surface molecules</p>
<p>Additional CD106 expression data in PBMCs</p>
<p>LAG3, HAVCR2, TIGIT, TNFRSF9, ENTPD1, and ITGAE expression using our scRNA-seq data volcano plots (exhausted CD8+ T-cell vs. the others) publicly available datasets</p>
<p>Influence of CD106 on various surface molecules</p>
<p>Multiplexed fluorescent immunohistochemistry</p>
<p>Additional CD106 functional analysis data</p>
<p>Sequencing summary</p>
<p>Additional <i>in vivo</i> data.</p>
<p>Patient characteristics for prognostic analyses</p>
<p>Additional CD106 expression data in PBMCs</p>
<p>Patient characteristics for scRNA/TCR-seq or flow cytometry</p>
<p>Frequencies of exhausted CD8+ T cell cluster</p>
<p>Patient characteristics for scRNA/TCR-seq or flow cytometry</p>
<p>Additional CD106 functional analysis data</p>